Screening the Silkroad: Small-Mid Cap High-Risk Names to Avoid: Q2 2019
The risk remains apparent - but list reduced in number over Q2 Q1-2019 Small-Mid Cap High-Risk list of stocks ( Screening the Silkroad: Small-Mid...
592 Views
Screening the Silkroad: Small-Mid Cap - Possible High-Risk Names: Q1 2019
Increasing risk apparent Q4-2018 Small-Mid Cap High-Risk screen ( Screening the Silkroad:Â Small-Mid Cap -Â High-Risk Names To Avoid Q4 2018 )...
663 Views
Eris Lifesciences Ltd - Q4FY18 Beats Expectations, FY19E on Track
Eris Lifesciences Limited (ERIS IN) reported Q4FY18 results recently. Performance Highlights Eris reported Q4FY18 consolidated revenues at Rs 2.1...
175 Views
ERIS Lifesciences Limited – Acquisition Led Growth Story
Eris Lifesciences Limited (ERIS IN)Â is engaged in the marketing and manufacturing of branded generic drugs and derives all its revenues from the...
344 Views
Laurus Labs- Moving up the Value Addition Ladder
Laurus Labs (LAURUS IN) is a research and development driven pharmaceutical company. It is a manufacturer of APIs for ARV, Hepatitis C, oncology...
341 Views